Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Denmark
/
Pharmaceuticals & Biotech
Create a narrative
Bavarian Nordic Community
CPSE:BAVA Community
3
Narratives
written by author
0
Comments
on narratives written by author
40
Fair Values set
on narratives written by author
Create a narrative
Bavarian Nordic
Popular
Undervalued
Overvalued
Community Investing Ideas
Bavarian Nordic
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
VIMKUNYA Launch Will Open Markets, But Approval Delays Could Impact Revenues
Key Takeaways Expansion in public preparedness and successful vaccine launches could significantly enhance revenue streams through government contracts and new territories. Advancements in new vaccine candidates indicate promising pipeline potential, supporting future revenue growth and market expansion.
View narrative
DKK 234.50
FV
1.0% overvalued
intrinsic discount
-2.71%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
30
users have followed this narrative
6 days ago
author updated this narrative
Bavarian Nordic
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Dependence On Key Contracts Will Hamper Performance Yet Suggest Promise
Key Takeaways Reliance on government contracts and a few high-value vaccines makes future revenues vulnerable to shifting spending priorities and competitive pressures. Manufacturing, regulatory, and demand uncertainties could cause volatile earnings and prevent expected margin improvements, despite efforts to diversify and scale operations.
View narrative
DKK 225.00
FV
5.3% overvalued
intrinsic discount
-4.17%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Bavarian Nordic
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Rising Global Vaccine Demand Will Spur Progress But Face Headwinds
Key Takeaways Accelerated manufacturing and strong travel health performance suggest margins and revenues may surpass expectations, signaling potential for significant long-term upside. Unique vaccine capabilities and expanding portfolio position the company to benefit from global health trends and increasing market opportunities, driving superior operational and financial growth.
View narrative
DKK 244.00
FV
2.9% undervalued
intrinsic discount
-2.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Your Valuation for
BAVA
BAVA
Bavarian Nordic
Your Fair Value
DKK
Current Price
DKK 236.90
26.0% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-606m
7b
2015
2018
2021
2024
2025
2027
2030
Revenue DKK 5.8b
Earnings DKK 1.2b
Advanced
Set Fair Value